Hyperbaric Oxygen Therapy (HBOT) and Hidradenitis Suppurativa
Evidence, Potential Benefits, and Limitations
Hyperbaric oxygen therapy is an emerging area of interest for HS wound healing. This page provides a balanced, evidence-based overview of what HBOT is, what current research shows, and what patients should understand before considering it.
What Hyperbaric Oxygen Therapy Is
Hyperbaric Oxygen Therapy (HBOT) is a medical treatment in which a person breathes 100% pure oxygen inside a specially pressurized chamber. The chamber increases atmospheric pressure to approximately 2 to 3 times normal levels, allowing oxygen to dissolve far more effectively into the bloodstream and reach damaged or oxygen-deprived tissues throughout the body.
HBOT is currently an FDA-approved treatment for several well-established medical conditions, including:
- Diabetic foot ulcers
- Radiation tissue injury
- Severe infections (e.g., necrotizing fasciitis)
- Carbon monoxide poisoning
- Chronic non-healing wounds
HBOT is not currently FDA-approved specifically for Hidradenitis Suppurativa.
Why Researchers Are Exploring HBOT for HS
Hidradenitis Suppurativa involves several biological processes that, in theory, could respond positively to increased oxygen delivery. Researchers have begun exploring HBOT as a potential adjunct therapy because of these overlapping mechanisms.
HS Biological Factors
- Chronic inflammation in the skin and follicles
- Impaired wound healing and sinus tract formation
- Bacterial biofilms resistant to standard antibiotics
- Low oxygen levels (hypoxia) in damaged tissue
How HBOT May Help
- Increasing oxygen delivery to affected and damaged skin
- Stimulating new blood vessel formation (angiogenesis)
- Improving immune response against bacteria in biofilms
- Reducing inflammatory signaling pathways
AI-generated educational diagram: Oxygen delivery to inflamed vs. healing tissue under hyperbaric pressure
What Current Research Shows
Scientific evidence for HBOT in HS is currently limited. Most available data comes from small observational studies, individual case reports, and patient series rather than large-scale clinical trials.
Some reports describe improvements such as faster healing of lesions, reduced drainage from sinus tracts, and temporary symptom relief in patients who underwent HBOT as part of wound care management. However, these findings come from small groups and cannot be generalized to all HS patients.
Important Research Limitations
- No large randomized controlled trials (RCTs) for HS
- Most evidence comes from small case reports and observational studies
- Long-term outcomes are not well established
- Most dermatology guidelines do not list HBOT as a standard HS treatment
Because of the current evidence gaps, most dermatology guidelines and clinical practice recommendations do not list HBOT as a standard treatment for Hidradenitis Suppurativa. Patients considering HBOT should be aware that they would be pursuing an off-label, experimental application.
Practical Considerations
Cost
- $200 to $500 per session
- 20 to 40 sessions typically required
- Total cost: $5,000 to $15,000
- Insurance coverage is uncommon for HS
Time Commitment
- 60 to 90 minutes per session
- Daily visits required
- 5 days per week
- Several weeks of therapy
Potential Risks
- Ear pressure injuries (barotrauma)
- Sinus discomfort or pain
- Temporary vision changes
- Rare oxygen toxicity seizures
- Claustrophobia in enclosed chambers
AI-generated educational illustration: A professional HBOT clinical facility
When HBOT May Be Considered
Some physicians may consider HBOT in specific clinical situations where standard wound care has not been sufficient. In these cases, HBOT is typically used as supportive wound-healing therapy rather than a primary treatment for HS itself.
Situations Where a Physician May Discuss HBOT
- Chronic non-healing HS wounds unresponsive to standard care
- Slow surgical wound healing after wide excision procedures
- Severe tissue damage where improved oxygen delivery may support recovery
Patients should only undergo HBOT under medical supervision at an accredited facility. Always discuss this option with a dermatologist or wound care specialist familiar with your HS history before pursuing treatment.
Important Perspective
At this time, hyperbaric oxygen therapy should be considered an emerging or experimental therapy for Hidradenitis Suppurativa. It is not a cure for HS and has not been proven to prevent new lesions or address the underlying disease process.
HBOT may help certain patients with wound healing, particularly those with chronic non-healing wounds or post-surgical recovery challenges. However, the evidence base remains thin, and the financial and time commitment is significant.
Patients interested in HBOT should discuss it with a qualified physician who can evaluate whether it is appropriate for their specific clinical situation.
Medical Disclaimer: This page is for educational purposes only and does not constitute medical advice. Hyperbaric oxygen therapy for HS is experimental and not a standard treatment. Always consult a qualified dermatologist or physician before making any treatment decisions.